Can-Fite BioPharma Ltd. (CANF)

Can-Fite BioPharma Stock Forecast

CANF's stock price has decreased by -86.84% in the past year and price targets may not have had time to catch up.

Stock Price Forecast

The 2 analysts that cover Can-Fite BioPharma stock have a consensus rating of "Strong Buy" and an average price target of $9,750, which forecasts a 234,275.00% increase in the stock price over the next year. The lowest target is $7,500 and the highest is $12,000.

Price Target: $9,750 (+234,275.00%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$7,500	$9,750	$12,000	$12,000
Change	+180188.5%	+234275.0%	+288361.5%	+288361.5%

* Price targets were last updated on Dec 17, 2025.

Analyst Ratings

The average analyst rating for Can-Fite BioPharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Aug '25	Sep '25	Oct '25	Nov '25	Dec '25	Jan '26
Strong Buy	2	2	2	2	2	2
Buy	0	0	0	0	0	0
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	2	2	2	2	2	2

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Jason Kolbert D. Boral Capital	D. Boral Capital	Strong Buy Maintains $33,000 → $12,000	Strong Buy	Maintains	$33,000 → $12,000	+288,361.54%	Dec 17, 2025
Jason Kolbert D. Boral Capital	D. Boral Capital	Strong Buy Maintains $33,000	Strong Buy	Maintains	$33,000	+793,169.23%	Nov 18, 2025
Swayampakula Ramakanth HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Initiates $7,500	Strong Buy	Initiates	$7,500	+180,188.46%	Nov 4, 2025
Jason Kolbert D. Boral Capital	D. Boral Capital	Strong Buy Maintains $33,000	Strong Buy	Maintains	$33,000	+793,169.23%	Sep 16, 2025
Jason Kolbert D. Boral Capital	D. Boral Capital	Strong Buy Maintains $33,000	Strong Buy	Maintains	$33,000	+793,169.23%	Sep 2, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

3.79M

Increased by 461.72%

from 674.00K

Revenue Next Year

3.00M

Decreased by -20.66%

from 3.79M

EPS This Year

-4.20

from -10.86

EPS Next Year

n/a

from -4.20

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	763.00K	853.00K	810.00K	743.00K	674.00K	3.79M	3.00M
Revenue Growth	-62.45%	11.80%	-5.04%	-8.27%	-9.29%	461.72%	-20.66%
EPS	-126.88	-82.48	-37.41	-17.92	-10.86	-4.20	-
EPS Growth	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	-	3	3

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027
High	3.9M	3.1M
Avg	3.8M	3.0M
Low	3.6M	2.9M

Revenue Growth

Revenue Growth	2025	2026	2027
High	478.2%	-18.3%
Avg	461.7%	-20.7%
Low	439.6%	-23.8%

EPS Forecast

EPS	2025	2026	2027
High	-4.33	-
Avg	-4.20	-
Low	-4.04	-

EPS Growth

EPS Growth	2025	2026	2027
High	-	-
Avg	-	-
Low	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.